Aileens Pharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Aileens Pharma General Information

Description

Developer of non-steroidal drugs designed for the treatment of atopic dermatitis and other skin diseases. The company's treatments challenge the lack of non-pharmacological therapies and focus on creating medicines for atopic dermatitis, seborrheic dermatitis, and psoriasis, enabling doctors and healthcare organizations to take protective measures and treat the symptoms related to skin diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Via Donatori Di Sangue
  • Nova Milanese, Lombardia
  • 20834 Milan
  • Italy
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1 Via Donatori Di Sangue
  • Nova Milanese, Lombardia
  • 20834 Milan
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aileens Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Apr-2026 Completed Generating Revenue
1. Early Stage VC (Series A) 18-Jul-2018 Completed Generating Revenue
To view Aileens Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Aileens Pharma Patents

Aileens Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4559469-A1 Compositions for prevention or treatment of dysbiosis Inactive 22-Nov-2023
AU-2022276457-A1 Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production Pending 21-May-2021
CA-3219681-A1 Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production Pending 21-May-2021
EP-4341379-A1 Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production Pending 21-May-2021
US-20240238352-A1 Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production Pending 21-May-2021 A61K35/74
To view Aileens Pharma’s complete patent history, request access »

Aileens Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aileens Pharma Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tech and Biomedical Foundation Venture Capital Minority
CDP Venture Capital (Rome) Venture Capital Minority
Panakes Partners Venture Capital Minority
To view Aileens Pharma’s complete investors history, request access »

Aileens Pharma FAQs

  • When was Aileens Pharma founded?

    Aileens Pharma was founded in 2018.

  • Where is Aileens Pharma headquartered?

    Aileens Pharma is headquartered in Milan, Italy.

  • What is the size of Aileens Pharma?

    Aileens Pharma has 4 total employees.

  • What industry is Aileens Pharma in?

    Aileens Pharma’s primary industry is Drug Discovery.

  • Is Aileens Pharma a private or public company?

    Aileens Pharma is a Private company.

  • What is Aileens Pharma’s current revenue?

    The current revenue for Aileens Pharma is .

  • How much funding has Aileens Pharma raised over time?

    Aileens Pharma has raised $3.5M.

  • Who are Aileens Pharma’s investors?

    Tech and Biomedical Foundation, CDP Venture Capital (Rome), and Panakes Partners have invested in Aileens Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process